Medical Cannabis Studies

A

• addiction (10)

• alzheimers/dementia (14)

• amyotrophic-lateral-sclerosis-als-lou-gehrigs (2)

• antibacterial (6)

• antioxidant (8)

• antiprion (1)

• anxiety (10)

• appetite (4)

• arthritis (4)

• asthma (1)

• attention-deficit-hyperactivity-disorder-adhd (5)

• autism (11)

• autoimmune (3)

B

• batten-disease (6)

• benefits (9)

• breast-cancer (7)

C

• cancer (94)

• cannabidiol-cbd (8)

• cardiovascular (8)

• cb1-receptor (8)

• cb2-receptor (9)

• cellular-function (4)

• cerebral-palsy (1)

• cognition (2)

• colon-cancer (8)

D

• d9-tetrahydrocannabinol-thc (4)

• d9-tetrahydrocannabinolic-acid-thca (1)

• diabetes (4)

• drug-interactions (2)

E

• emesis (6)

• endocannabinoid-system-ecs (45)

• endocrine-system (3)

• epilepsy (30)

F

• fibromyalgia (2)

• fibrosis (1)

G

• gastrointestinal-disease (6)

• general (20)

• glaucoma (1)

• glioblastoma (1)

• glioma (9)

H

• health-care (1)

• hiv (7)

• huntingtons-disease (1)

I

• immune-function (8)

• infant-development (1)

• inflammation (9)

• ischemia (3)

K

• krabbe-disease (4)

L

• liver (2)

• lung-cancer (2)

• lupus (1)

M

• memory (3)

• mental-illness (14)

• migraine (1)

• mitochondria (1)

• multiple-sclerosis (15)

N

• national-institute-on-drug-abuse-nida (1)

• nausea (1)

• nervous-system (4)

• neuro-protective-and-neuro-generative (7)

P

• pain (29)

• pancreatitis (1)

• prostate-cancer (2)

S

• schizophrenia (2)

• skin (1)

• sports (3)

T

• thc (1)

• therapeutic (1)

• traumatic-brain-injury-tbi (1)

• View All (505)
  • Association of the Cannabinoid Receptor Gene (CNR1) With ADHD and Post-Traumatic Stress Disorder (2009)

    These observations suggest that the cannabinoid receptor gene (CNR1) may be a risk factor for ADHD and possibly TTPT, and that this gene deserves further investigation for a role in neuropsychiatric disorders. View study

  • Associations between Adolescent Cannabis Use and Neuropsychological Decline (no year)

    This study focused on the associations between cannabis use in adolescents and the neuropsychological decline. According to the results, it could be concluded that the short-term use of cannabis in adolescence does not seem to cause a decrease in the IQ or alter executive functions, even when cannabis use reaches the level of dependence. View study

  • Autism-Associated Neuroligin-3 Mutations Commonly Disrupt Tonic Endocannabinoid Signaling (2013)

    Neuroligin-3 is specifically necessary for tonic endocannabinoid signaling. This suggests that alterations in endocannabinoid signaling may contribute to the pathophysiology of autism. View study

  • Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease (2013)

    According to the results obtained using mice as a sample, the positive effect of cannabigerol (CBG), a cannabinoid derivative of non-psychotropic cannabis, in a murine model of colitis could be verified. Its use is possible for the treatment of patients with inflammatory bowel disease (IBD). Because CBG attenuated murine colitis, it reduced the production of nitric oxide in macrophages (effect modulated by the CB2 receptor) and reduced ROS formation in intestinal epithelial cells View study

  • Benefits and adverse effects of cannabis use among adults with persistent pain (2018)

    Increasingly, states are legalizing cannabis for recreational use. Improved accessibility can allow adults with pain to use cannabis more liberally. The purpose of this study was to examine the perceived effects of cannabis in adults who have been prescribed opioids for persistent pain. View study

  • Benefits and Harms of Cannabis in Chronic Pain or Post-traumatic Stress Disorder: A Systematic Review [Internet] (2017)

    Recent studies indicate that between 45% and 80% of people who seek cannabis for medical purposes do so to control pain, which suggests its therapeutic potential in patients with chronic pain. View study

  • Biphasic Effects of Cannabinoids on Acetylcholine Release in the Hippocampus: Site and Mechanism of Action (2003)

    This research was based on the study of the biphasic effects of cannabinoids on the release of acetylcholine in the hippocampus, site and mechanism of action. The results found in this study could help and provide a theoretical framework for understanding endocannabinoids as modulators of neuronal activity dependent on the state. View study

  • Blood pressure regulation by endocannabinoids and their receptors (2005)

    This research focuses on analyzing the in vivo hypotensive and cardiodepressant effects of cannabinoids mediated by cannabinoid and TRPV1 receptors and new therapeutic strategies related to the treatment of hypertension. View study

  • Brain CB2 Receptors: Implications for Neuropsychiatric Disorders (2010)

    The CB2 receptor as a possible target for the treatment of neuroinflammatory and neurodegenerative disorders. View study

  • Can You Pass the Acid Test? Critical Review and Novel Therapeutic Perspectives of D9-Tetrahydrocannabinolic Acid A.pdf (2016)

    This study seeks to make a critical analysis and offer new therapeutic perspectives of D9-tetrahydrocannabinolic acid View study

  • Canabimimetic plants: are they new cannabinoidergic modulators. (2019)

    The objective of this review was to provide critical and complete assessment of the botanical, chemical and therapeutic aspects of cannabimimetic plants to evaluate their spread in the world and medicinal potentiality. View study

  • Cannabidiol (CBD) and its analogs: A review of their effects on inflammation (2015)

    Until 1963 the structure of the CBD was not completely elucidated, and THC was thought to be the most powerful and active component of cannabis, a belief that was mostly due to its psychoactive effects. Therefore, the therapeutic benefits of CBD were minimized for a long time. This study focuses on the therapeutic and anti-inflammatory benefits of CBD. View study

  • Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function (2012)

    CBD has been shown to have short-term neuroprotective effects in the immature brain, suggesting that it could be used as a neuroprotective agent for neonatal hypoxiaeischemia. View study

  • Cannabidiol and (?)?9-tetrahydrocannabinol are neuroprotective antioxidants (1998)

    These data suggest that the non-psychotropic cannabinoid of natural origin CBD has therapeutic potential for the treatment of neurological oxidative disorders such as cerebral ischemia. View study

  • Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease (2011)

    Based on the results of this study it was found that cannabidiol (CBD) has the ability to modulate the function of the microglial cell in vitro, inducing beneficial effects in an in vivo model of Alzheimer’s disease, thus indicating that CBD has the potential to represent a new therapeutic approach to treat this disease. View study

  • Cannabidiol Arrests Onset of Autoimmune Diabetes in NOD Mice (2008)

    The results of the studies carried out on non-obese female mice with a tendency to diabetes (NOD), show that when cannabidiol (CBD) is administered by presenting the mice with a latent or initial state of diabetes, the mice reflect improvement of the disease. This reinforces the assumption that CBD, could be used in humans, for the treatment of type 1 diabetes. View study

  • Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells (2007)

    CBD would help treat breast cancer since it can significantly decrease the development of metastatic cells. View study

  • Cannabidiol as a potential treatment for psychosis (2013)

    A review that concisely describes the role of the endocannabinoid system in the development of psychosis and provides an overview of several currently available studies on the antipsychotic properties of CBD. View study

  • Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. (2019)

    Epilepsy is one of the most common chronic brain disorders that affects around 70 million people worldwide. The objective of this article was to make a critical review of the pharmacology of Cannabidiol (CBD) and the most recent clinical studies who evaluated its efficacy and safety as a complementary treatment for seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS). View study

  • Cannabidiol as an Emergent Therapeutic Strategy for Lessening the Impact of Inflammation on Oxidative Stress (2011)

    This review discusses recent research that states that CBD can contribute to the treatment of diseases and disorders such as rheumatoid arthritis, type I and II diabetes, atherosclerosis and Alzheimer’s disease. View study

  • Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence (2015)

    Some preclinical studies say that cannabidiol (CBD) can have therapeutic properties on opiates, cocaine and psychostimulant addiction. They also suggest that CBD may be beneficial for the consumption of cannabis and tobacco in humans. However, more studies are needed to fully verify the potential of the CBD. View study

  • Cannabidiol as potential anticancer drug (2012)

    There is emerging evidence to suggest that cannabidiol (CBD) is a potent inhibitor of cancer growth and spread. Its effectiveness is linked to its ability to target multiple cellular pathways that control tumorigenesis through the modulation of different intracellular signals depending on the type of cancer considered. View study

  • Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy (2010)

    These results indicate that the CBD could have an enormous therapeutic potential to treat diabetic and cardiovascular complications due to its ability to reduce inflammation, oxidative stress, nitration, fibrosis and cell death. View study

  • Cannabidiol did not induce teratogenicity or neurotoxicity in exposed zebrafish embryos. (2018)

    The toxicity studies of Cannabidiol (CBD) are of great importance to ensure the safety of patients. In this context, the morphological analysis of the zebrafish can contribute to evaluate the teratogenic potential, as well as the evaluation of the acetylcholinesterase activity and the motor activity of the zebrafish are valuable tools to verify the potential of neurotoxicity. The results suggest that the effects observed after exposure to CBD are closely related to the CB1 receptor that is present in the zebrafish from the earliest stages of development. View study